Medicine
Complera 200 mg/25 mg/300 mg tablet
Complera 200 mg/25 mg/300 mg tablet is a prescription medicine containing Emtricitabine, Rilpivirine and Tenofovir disoproxil for oral use, marketed by Gilead Sciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25 °C (77 °F), excursions permitted to 15 °C–30 °C (59 °F–86 °F).
Key facts
- Active ingredient (INN)
- Emtricitabine, Rilpivirine and Tenofovir disoproxil
- Brand
- Complera
- Strength
- 200 mg/25 mg/300 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Gilead Sciences
- Manufacturer
- Gilead Sciences
- Origin register
- US FDA, United States
- Storage
- Store at 25 °C (77 °F), excursions permitted to 15 °C–30 °C (59 °F–86 °F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AR08 Emtricitabine, Rilpivirine and Tenofovir disoproxil
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 August 2011
- Identifiers
- RxCUI 1147334, 1147337DailyMed set ID d637cfab-f1e8-4eb3-a1b3-f85ca3bec612NDC 61958-1101Application NDA202123
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 61958-1101-1 | Gilead Sciences | 10 August 2011 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Emtricitabine, Rilpivirine and Tenofovir disoproxil 200 mg/25 mg/300 mg tablet.
Clinical summary
Emtricitabine, Rilpivirine and Tenofovir disoproxil is a fixed-dose combination of a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor, a hepatitis B virus nucleoside analog reverse transcriptase inhibitor and a human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor. MedsAcross supplies Emtricitabine, Rilpivirine and Tenofovir disoproxil for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Emtricitabine, Rilpivirine and Tenofovir disoproxilFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- COMPLERA prescribing information (Gilead Sciences) · U.S. National Library of Medicine, DailyMed
- Eviplera: European public assessment report (EPAR) · European Medicines Agency
Need Complera 200 mg/25 mg/300 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.